DA Davidson Issues Pessimistic Estimate for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at DA Davidson decreased their Q1 2025 earnings estimates for USANA Health Sciences in a research note issued on Thursday, February 27th. DA Davidson analyst C. Xue now forecasts that the company will post earnings per share of $0.76 for the quarter, down from their previous estimate of $0.83. DA Davidson currently has a “Neutral” rating and a $36.00 price objective on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.76 EPS, FY2025 earnings at $2.38 EPS, FY2025 earnings at $2.38 EPS and FY2026 earnings at $2.59 EPS.

USNA has been the topic of a number of other reports. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Trading Down 14.0 %

USNA opened at $28.57 on Friday. The company has a market cap of $544.54 million, a P/E ratio of 10.10, a P/E/G ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a 12 month low of $27.71 and a 12 month high of $50.32. The business’s 50-day moving average price is $33.50 and its 200-day moving average price is $36.56.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $213.61 million for the quarter, compared to analysts’ expectations of $208.82 million.

Institutional Trading of USANA Health Sciences

A number of institutional investors have recently modified their holdings of USNA. Martingale Asset Management L P raised its position in USANA Health Sciences by 2.1% during the 3rd quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock valued at $634,000 after purchasing an additional 340 shares during the last quarter. KBC Group NV increased its stake in shares of USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the period. R Squared Ltd purchased a new position in shares of USANA Health Sciences during the fourth quarter valued at approximately $28,000. Safe Harbor Fiduciary LLC bought a new position in shares of USANA Health Sciences during the third quarter valued at approximately $30,000. Finally, Exchange Traded Concepts LLC lifted its stake in USANA Health Sciences by 11.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company’s stock worth $308,000 after acquiring an additional 869 shares during the period. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.